Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ACT-20-MSC · ACT-20

Cell therapy (Stem-cell derived)

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is ACT-20-MSC?

ACT-20-MSC is a mesenchymal stem cell therapy administered as 1 million cells per kilogram body weight in conditioned media. It is studied in COVID-19 pneumonia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ACT-20
Drug type
Cell therapy (Stem-cell derived)
Therapy area
Infectious disease
In trials of
ASBP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04398303 Phase 1/2 COVID-19 Pneumonia Unknown ASBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19 Pneumonia

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.